His main research interest is the biology of plasma cell dyscrasias and especially the biology of bone disease in multiple myeloma (MM). In more than 600 papers in peer-reviewed journals, Dr Terpos has reported the significant role of RANKL and osteoprotegerin axis, CCL-3 (MIP-1alpha), Wnt and TGF-beta signalling in myeloma bone disease and myeloma cell growth. He has studied the predictive value of markers of bone remodelling and osteoclast function in myeloma progression and patients’ survival. He has evaluated the effect of bisphosphonates and different anti-myeloma therapies including ASCT, IMiDs- and bortezomib-based regimens on bone metabolism. He has studied the biology and prevalence of osteonecrosis of the jaw in myeloma patients who receive bisphosphonates. Dr Terpos also works on the role of angiogenesis in MM and Waldenstrom’s Macroglobulinemia, renal impairment in MM, and apoptotic proteins in the clinical outcome of patients with plasma cell dyscrasias. In clinical research, Dr Terpos has participated and participates in all important clinical trials with novel agents (pomalidomide, carfilzomib, ixazomib, daratumumab etc) in the field of multiple myeloma. Dr Terpos has studied also the biology and management of bone disease in thalassemia and sickle-cell disease, as well as of other hematological disorders including hemophilia, Paget's disease and histiocytosis.